首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1830990

子宮頸癌治療市場

Cervical Cancer Treatment Market

出版日期: 2025年09月24日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

子宮頸癌治療市場預計將從 2024 年的 102.6 億美元增加到 2031 年的 149.1 億美元，2025 年至 2031 年的預計複合年成長率為 5.7%。

市場洞察與分析師觀點：子宮頸癌治療市場的預測可以幫助利害關係人制定成長策略。

子宮頸癌是指發生在子宮頸細胞（即連接陰道的子宮下段）的癌症。 90% 的子宮頸癌病例由 HPV 感染引起，可透過抹片篩檢確診。子宮頸癌發生率的上升和 HPV 感染的增加是推動子宮頸癌治療市場成長的主要因素。然而，對診斷和治療方案缺乏認知對市場成長構成了挑戰。子宮頸癌治療市場的趨勢包括加強對子宮頸癌診斷和治療的研發。

成長動力與挑戰：子宮頸癌發生率上升推動市場成長在全球範圍內，癌症正成為死亡的主要原因。根據世界衛生組織 (WHO) 的數據，2019 年，癌症是 183 個國家 70 歲以下人口的首要死因，也是其他 123 個國家的第四大死因。此外，WHO 2021 年 3 月的資料顯示，2020 年有近 1,000 萬人死於各種癌症。由於全球女性子宮頸癌發生率不斷上升，子宮頸癌治療市場經歷了顯著成長。 WHO 報告稱，子宮頸癌每年奪走超過 27 萬名女性的生命，由於診斷較晚，低收入國家的死亡率更高。

子宮頸癌發生率的上升給全球醫療體系帶來了巨大壓力。國際癌症研究機構 (IARC) 估計，到 2040 年，全球新增癌症病例將達到約 2,750 萬，並導致約 1.63 億人死亡。生活方式的改變、吸煙、體力活動減少以及不確定的健康和環境條件等因素預計將在未來幾年加劇癌症負擔。因此，控制和預防全球癌症病例的上升至關重要。

導致子宮頸癌高發病率和高死亡率的因素包括民眾、醫療服務提供者和政策制定者缺乏認知；優質醫療服務和子宮頸篩檢計畫的機會有限；以及轉診系統不完善。在已開發國家，由於細胞學篩檢機會的改善和早期子宮頸病變的及時治療，子宮頸癌的發生率和死亡率都有所下降。在中低收入國家 (LMIC) 進行以人群為基礎的子宮頸篩檢並提高其接受度對於降低子宮頸癌死亡率至關重要。提高對早期性行為、多名男性性伴侶、HPV 8、9 和 10 型相關風險、早期足月妊娠、長期口服避孕藥使用以及 HIV 感染等風險因素的認知，可以鼓勵人們參與篩檢計畫。提高對子宮頸癌症狀（包括經間期出血、停經後出血、性交後出血、惡臭陰道分泌物和下腹痛）的認知，可以促使女性及早就醫。因此，民眾對子宮頸癌認知的缺乏是子宮頸癌治療市場成長的一大障礙。

策略洞察報告細分和範圍：細分分析：市場按類型分為鱗狀細胞癌、腺鱗狀細胞癌和腺癌。鱗狀細胞癌在2022年子宮頸癌治療市場中佔據較大佔有率，預計2022年至2030年期間的複合年成長率將更高。按產品分類，市場分為外科手術、放射療法、化療、免疫療法和治療性疫苗，預計到2030年外科手術將保持相當大的佔有率。就最終用戶而言，市場細分為醫院、家庭護理、癌症中心和其他，其中醫院在2022年佔據最大佔有率。

區域分析：子宮頸癌治療市場報告涵蓋北美、歐洲、亞太地區、中東和非洲以及南美和中美等地區。 2022 年，北美佔據子宮頸癌治療市場的最大佔有率，其中美國佔有相當大的佔有率。正在進行的研發活動、政府和私營部門的財政支持、IT 和製藥公司之間的合作以及神經系統疾病發病率的上升是美國市場成長的主要驅動力。此外，預計政府旨在改進檢測程序的措施將在預測期內使市場受益。擴大採用與罕見疾病相關的法規可能會為市場成長創造機會，例如美國癌症協會 (ACS) 於 2020 年 9 月修訂了子宮頸癌篩檢指南。

子宮頸癌治療市場報告範圍：產業發展與未來機會：子宮頸癌治療市場的分析涉及識別和評估產業關鍵參與者。主要市場參與者的一些措施包括：

2024年1月，輝瑞公司和Genmab A/S宣布，美國食品藥物管理局（FDA）已接受其補充生物製品許可申請（sBLA），以轉換TIVDAK（tisotumab vedotin-tftv）的批准，用於治療一線治療後病情進展的複發性或轉移性子宮頸癌患者。該申請已被授予優先審查資格，處方藥使用者付費法（PDUFA）的目標截止日期為2024年5月9日。 2023年9月，廣州譽衡生物科技股份有限公司（GloriaBio）宣布，全人源抗PD-1單株抗體Zimberelimab注射液（YuTuo，GLS-010）獲得中國國家藥品監督管理局（NMPA）的上市許可。此注射可作為複發性或轉移性子宮頸癌 (R/M CC) 患者的單藥療法，這使得 Zimberelimab 成為全球第三個獲準用於治療子宮頸癌的免疫檢查點抑制劑 (ICI) 抗體，也是中國首個獲準的抗體。競爭格局與重點公司：子宮頸癌治療市場報告中介紹的重點公司包括羅氏公司 (F.Hoffmann-La Roche Ltd)、默克夏普 (Merck Sharp)、Dohme Corp.、葛蘭素史克公司 (GlaxoSmithKline plc.)、基因泰克公司 (Genentech Inc.)、安進公司 (GlaxoSmithKline plc.)、基因泰克公司 (Genentech Inc.)、安進公司 (Amgenx Inc.) Inc. (Pfizer Inc.) 和阿斯特捷利康 (AstraZeneca)。這些公司專注於擴大產品供應，以滿足日益成長的全球需求。他們的國際影響力使他們能夠服務廣泛的客戶群，從而擴大其市場覆蓋範圍。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 11 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 12 章：競爭格局

關鍵參與者的熱圖分析
公司定位與集中度

第 13 章：子宮頸癌治療市場 - 主要公司簡介

F. Hoffmann-La Roche Ltd
Merck Sharp and Dohme Corp.
GlaxoSmithKline plc.
Genentech, Inc.
Amgen Inc.
Advaxis, Inc.
Biocon
Allergan, Inc
Pfizer Inc
AstraZeneca

第 14 章：附錄

簡介目錄

Product Code: TIPRE00004058

The cervical cancer treatment market is expected to increase from US$ 10.26 billion in 2024 to US$ 14.91 billion by 2031, with a projected CAGR of 5.7% from 2025 to 2031.

Market Insights and Analyst Perspective:The forecast for the cervical cancer treatment market can assist stakeholders in formulating their growth strategies.

Cervical cancer is defined as cancer that develops in the cervix cells, which is the lower section of the uterus connecting to the vagina. In 90% of cases, cervical cancers are caused by HPV infections and are identified through smear screening. The rising incidence of cervical cancer and the increase in HPV infections are the primary factors propelling the growth of the cervical cancer treatment market. However, the lack of awareness regarding diagnosis and treatment options poses a challenge to market growth. Trends in the cervical cancer treatment market include heightened R&D efforts for cervical cancer diagnostics and therapeutics.

Growth Drivers and Challenges:Rising Incidence of Cervical Cancer Drives Market Growth

Globally, cancer is becoming a leading cause of death. According to the World Health Organization (WHO), cancer was the leading cause of death for individuals under 70 in 183 countries, and the fourth leading cause in 123 other nations in 2019. Additionally, WHO data from March 2021 indicated that nearly 10 million deaths in 2020 were due to various cancers. The cervical cancer treatment market has experienced significant growth, attributed to the increasing incidence of cervical cancer among women worldwide. The WHO reports that cervical cancer claims the lives of over 270,000 women annually, with higher mortality rates in low-income countries due to late-stage diagnosis.

The rising incidence of cervical cancer is placing a strain on healthcare systems globally. The International Agency for Research on Cancer (IARC) estimates that the global burden of new cancer cases will reach approximately 27.5 million, leading to around 163 million deaths by 2040. Factors such as lifestyle changes, smoking, decreased physical activity, and uncertain health and environmental conditions are expected to exacerbate the cancer burden in the coming years. Therefore, it is crucial to control and prevent the rising number of cancer cases worldwide.

Factors contributing to the high incidence and mortality rates of cervical cancer include a lack of awareness among populations, healthcare providers, and policymakers; limited access to quality healthcare services and cervical screening programs; and inadequate referral systems. In developed countries, cervical cancer incidence and mortality have decreased due to improved access to cytological screening and prompt treatment of early cervical lesions. Implementing population-based cervical screening and enhancing its acceptance in low- and middle-income countries (LMICs) is vital for reducing cervical cancer mortality. Increasing awareness of risk factors such as early sexual activity, multiple male sexual partners, the risks associated with HPV types 8, 9, and 10, early full-term pregnancies, prolonged oral contraceptive use, and HIV infections may encourage participation in screening programs. Improved awareness of cervical cancer symptoms, including intermenstrual bleeding, postmenopausal bleeding, post-coital bleeding, foul vaginal discharge, and lower abdominal pain, could prompt women to seek early medical attention. Thus, the lack of awareness about cervical cancer among populations is a significant barrier to the growth of the cervical cancer treatment market.

Strategic Insights

Report Segmentation and Scope:Segmental Analysis:The market is categorized by type into squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. The squamous cell carcinoma segment held a larger share of the cervical cancer treatment market in 2022 and is expected to exhibit a higher CAGR from 2022 to 2030. By product, the market is divided into surgery, radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines, with the surgery segment anticipated to maintain a significant share by 2030. In terms of end users, the market is segmented into hospitals, homecare, cancer centers, and others, with hospitals holding the largest share in 2022.

Regional Analysis:The cervical cancer treatment market report covers regions including North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America accounted for the largest share of the cervical cancer treatment market in 2022, with the US holding a significant portion. Ongoing R&D activities, government and private sector financial support, collaborations between IT and pharmaceutical companies, and the rising incidence of neurological diseases are key drivers of market growth in the US. Additionally, government initiatives aimed at improving testing procedures are expected to benefit the market during the forecast period. The increasing adoption of regulations related to rare diseases is likely to create opportunities for market growth, such as the American Cancer Society (ACS) revising cervical cancer screening guidelines in September 2020.

Cervical Cancer Treatment Market Report Scope

Industry Developments and Future Opportunities:The analysis of the cervical cancer treatment market involves identifying and assessing key players in the industry. Some initiatives by major market players include:

In January 2024, Pfizer Inc. and Genmab A/S announced that the US Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) to convert TIVDAK's (tisotumab vedotin-tftv) approval for treating patients with recurrent or metastatic cervical cancer whose disease progresses after first-line therapy. The application has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 9, 2024.

In September 2023, Guangzhou Gloria Biosciences (GloriaBio) announced that Zimberelimab injection (YuTuo, GLS-010), a fully human anti-PD-1 monoclonal antibody, received marketing approval from the China National Medical Products Administration (NMPA). This injection can be used as a monotherapy for patients with recurrent or metastatic cervical cancer (R/M CC), making zimberelimab the third immune checkpoint inhibitor (ICI) antibody approved globally for cervical cancer treatment and the first authorized in China.

Competitive Landscape and Key Companies:Key companies profiled in the cervical cancer treatment market report include F.Hoffmann-La Roche Ltd, Merck Sharp, Dohme Corp., GlaxoSmithKline plc., Genentech Inc., Amgen Inc., Advaxis Inc., Biocon, Allergan Inc., Pfizer Inc., and AstraZeneca. These companies are focused on expanding their product offerings to meet the growing global demand. Their international presence enables them to serve a wide customer base, thereby enhancing their market reach.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Cervical Cancer Treatment Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Cervical Cancer Treatment Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Cervical Cancer Treatment Market - Global Market Analysis

6.1 Cervical Cancer Treatment - Global Market Overview
6.2 Cervical Cancer Treatment - Global Market and Forecast to 2030

7. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Type, 2020-2030

7.1 Overview
7.2 Adenocarcinoma
7.3 Adenosquamous carcinoma
7.4 Squamous cell carcinoma

8. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Product, 2020-2030

8.1 Overview
8.2 Gardasil/Gardasil 9
8.3 Cervarix
8.4 Avastin
8.5 Keytruda
8.6 Others

9. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

9.1 Overview
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 Online Pharmacies

10. Cervical Cancer Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

10.1 North America
- 10.1.1 North America Cervical Cancer Treatment Market Overview
- 10.1.2 North America Cervical Cancer Treatment Market Revenue and Forecasts to 2030
- 10.1.3 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Type
- 10.1.4 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Product
- 10.1.5 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
- 10.1.6 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Cervical Cancer Treatment Market
    - 10.1.6.1.1 United States Cervical Cancer Treatment Market, by Type
    - 10.1.6.1.2 United States Cervical Cancer Treatment Market, by Product
    - 10.1.6.1.3 United States Cervical Cancer Treatment Market, by Distribution Channel
  - 10.1.6.2 Canada Cervical Cancer Treatment Market
    - 10.1.6.2.1 Canada Cervical Cancer Treatment Market, by Type
    - 10.1.6.2.2 Canada Cervical Cancer Treatment Market, by Product
    - 10.1.6.2.3 Canada Cervical Cancer Treatment Market, by Distribution Channel
  - 10.1.6.3 Mexico Cervical Cancer Treatment Market
    - 10.1.6.3.1 Mexico Cervical Cancer Treatment Market, by Type
    - 10.1.6.3.2 Mexico Cervical Cancer Treatment Market, by Product
    - 10.1.6.3.3 Mexico Cervical Cancer Treatment Market, by Distribution Channel
10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Cervical Cancer Treatment Market - Key Company Profiles

13.1 F. Hoffmann-La Roche Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Merck Sharp and Dohme Corp.
13.3 GlaxoSmithKline plc.
13.4 Genentech, Inc.
13.5 Amgen Inc.
13.6 Advaxis, Inc.
13.7 Biocon
13.8 Allergan, Inc
13.9 Pfizer Inc
13.10 AstraZeneca